Daily Anesthesiology Research Analysis
Analyzed 94 papers and selected 3 impactful papers.
Summary
Three impactful perioperative studies stand out today: a double-blind RCT shows intraoperative sodium oxybate may reduce postoperative delirium specifically for morning orthopedic surgeries; a nationwide registry analysis links preoperative dual antiplatelet therapy to higher bleeding and mortality in urgent CABG; and an individual patient data meta-analysis reveals markedly better—but still limited—outcomes for postcardiotomy VA-ECMO in patients ≤40 years.
Research Themes
- Chronotherapeutic strategies for postoperative delirium prevention
- Perioperative antiplatelet management in urgent cardiac surgery
- Risk stratification and bridging strategies in postcardiotomy VA-ECMO
Selected Articles
1. Prophylactic effect of intraoperative sodium oxybate on postoperative delirium in older patients undergoing major orthopedic surgery: a randomized clinical trial.
In a double-blind RCT of 332 older adults undergoing spine or joint surgery, intraoperative sodium oxybate did not reduce delirium overall but significantly lowered POD incidence in morning surgeries (7.3% vs 18.5%; RR 0.395). No effect was seen for afternoon surgeries, and safety, recovery, and sleep measures were similar between groups.
Impact: This is one of the first RCTs to show a time-of-day–dependent effect of a perioperative intervention on delirium, opening a path for chronotherapy in POD prevention.
Clinical Implications: Consider time-of-day when targeting POD prevention: sodium oxybate may be an option for morning orthopedic cases if institutional workflows and contraindications permit, while offering no apparent benefit for afternoon surgeries.
Key Findings
- Overall POD incidence did not differ between sodium oxybate and placebo (10.3% vs 13.5%; P=0.372).
- Morning surgery subgroup showed reduced POD with sodium oxybate (7.3% vs 18.5%; RR 0.395, 95% CI 0.161-0.968; P=0.033).
- No significant effects in afternoon surgeries; safety, recovery metrics, pain, and sleep quality were similar after FDR correction.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with adequate sample size
- Pre-registered trial with multiplicity control (FDR correction) and prespecified subgroup analyses by surgery time
Limitations
- Efficacy limited to a subgroup (morning surgeries), with no overall population effect
- Single-country setting; potential generalizability and implementation constraints
Future Directions: Confirm time-of-day effects in multicenter RCTs, test dosing/timing optimization, and evaluate integration with multimodal delirium prevention bundles.
BACKGROUND: Postoperative delirium (POD) represents a significant challenge in perioperative care, particularly among older surgical patients. This acute neuropsychiatric syndrome is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Sleep disturbance has emerged as a significant modifiable risk factor for POD. Sodium oxybate (SO), a gamma-aminobutyric acid B (GABA METHODS: This randomized, double-blind, placebo-controlled trial enrolled 332 older patients undergoing elective spine and joint replacement surgery. Participants received either sodium oxybate (30 mg kg RESULTS: POD incidence showed no significant difference between groups in unstratified population (10.3% vs. 13.5%, P = 0.372). However, subgroup analysis revealed protective effects in morning surgery patients (7.3% vs. 18.5%, relative risk (RR) = 0.395, 95% confidence intervals (CI) = 0.161-0.968, P = 0.033), while no effect was observed in the afternoon surgery group (13.3% vs. 8.5%, P = 0.318). Among patients with delirium, no significant differences were observed in delirium severity, onset timing, delirium duration, or subtype distribution after false discovery rate (FDR) correction. No significant differences were found in sleep quality, maximal pain score, or safety parameters between groups after FDR correction. CONCLUSIONS: Intraoperative sodium oxybate demonstrates possible time-specific efficacy, significantly reducing POD incidence exclusively in older patients undergoing morning orthopedic surgery, while demonstrating an acceptable safety profile with no significant adverse effects on anesthesia recovery or hemodynamic parameters, suggesting a potential chronotherapeutic approach to POD prevention. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2300078594. Registered on 2023-12-13.
2. Preoperative dual antiplatelet therapy increases risk after urgent coronary bypass surgery: A Netherlands heart registration study.
Using a nationwide registry of 6,913 urgent CABG cases, preoperative DAPT within 48 hours was associated with higher reintervention, transfusion, and surgical mortality compared with aspirin alone, even after propensity matching and multivariable adjustment. Marked interhospital variation (12–84%) highlights inconsistent practice.
Impact: Provides large-scale, adjusted evidence that recent preoperative DAPT increases bleeding and mortality risks in urgent CABG, informing perioperative antiplatelet management.
Clinical Implications: For urgent CABG after ACS, clinicians should reassess timing and reversal strategies for P2Y12 inhibition, employ blood conservation and hemostasis plans, and advocate for standardized institutional pathways to reduce unwarranted variation.
Key Findings
- Preoperative DAPT within 48 hours independently increased reintervention (OR 1.78), transfusion (OR 1.85), and surgical mortality (OR 2.02).
- Large interhospital variation in DAPT use (12–84%) indicates inconsistent practices across centers.
- Propensity score matching and multivariable models support robustness of associations.
Methodological Strengths
- Large nationwide registry with multicenter representation and contemporary practice
- Use of propensity score matching and multivariable adjustment to mitigate confounding
Limitations
- Observational design cannot eliminate residual confounding or indication bias
- Limited granularity on specific P2Y12 agents, dosing, platelet function testing, and reversal strategies
Future Directions: Prospective studies to refine timing, reversal, and bridging strategies; development and validation of standardized perioperative antiplatelet pathways for urgent CABG.
OBJECTIVE: Dual antiplatelet therapy (DAPT) is standard care after acute coronary syndrome, but its perioperative management before urgent coronary artery bypass grafting (CABG) remains controversial. By using data from the Netherlands Heart Registration, a nationwide Dutch registry, we sought to assess the impact of recent preoperative DAPT on surgical and postoperative outcomes in patients undergoing urgent CABG after acute coronary syndrome. METHODS: In this multicenter retrospective cohort study, 6913 patients undergoing urgent isolated CABG within 90 days of acute coronary syndrome were analyzed. Patients receiving DAPT (aspirin + P2Y12 inhibitor within 48 hours preoperatively) were compared with those on aspirin alone. Propensity score matching and multivariable logistic regression were used to adjust for confounding. RESULTS: Recent DAPT use was independently associated with increased perioperative bleeding complications, including greater rates of reintervention (odds ratio [OR], 1.78), transfusion (OR, 1.85), and surgical mortality (OR, 2.02). Considerable interhospital variation in DAPT use (12%-84%) underscores inconsistent practices across Dutch cardiac surgery centers. CONCLUSIONS: Recent DAPT before urgent CABG is independently associated with significantly increased perioperative bleeding risk, transfusion requirements, and mortality. The substantial interhospital variation in DAPT use across Dutch cardiac surgery centers further underscores the need for standardized, evidence-based guidelines to optimize antiplatelet management in high-risk patients with coronary syndrome requiring surgical revascularization.
3. Outcomes after postcardiotomy venoarterial extracorporeal membrane oxygenation in young patients: An individual patient data meta-analysis.
This IPD meta-analysis of 1,268 postcardiotomy VA-ECMO patients across 25 hospitals found age ≤40 years as a favorable cutoff: older patients had markedly higher in-hospital and 24-month mortality (adjusted OR 3.267; adjusted HR 3.530). Despite better outcomes in the young, mortality remains substantial and bridging to VAD/transplant was infrequent.
Impact: Provides age-based risk stratification from IPD across centers, informing candidacy, counseling, and consideration of earlier heart-replacement strategies in postcardiotomy shock.
Clinical Implications: Younger postcardiotomy VA-ECMO patients (≤40 years) have better survival but still face high mortality; centers should evaluate candidacy for early bridging to VAD or transplant and optimize perioperative complication mitigation.
Key Findings
- Age >40 years associated with higher in-hospital mortality (crude 68.8% vs 43.1%; adjusted OR 3.267, 95% CI 1.970–5.425).
- Mortality at 24 months higher in >40 years (crude 73.7% vs 45.0%; adjusted HR 3.530, 95% CI 2.571–4.844).
- Bridging to VAD/heart transplantation was more frequent in ≤40 years (11.0%) than >40 years (2.9%), yet overall utilization remained low.
Methodological Strengths
- Individual patient data meta-analysis across 25 centers enabling adjusted analyses
- Systematic identification of studies with harmonized endpoints and age cutoff determination
Limitations
- Observational IPD; potential selection and center-level heterogeneity
- Limited data on indications, ECMO management nuances, and criteria for VAD/HTx bridging
Future Directions: Develop age- and physiology-informed selection tools, test early bridge strategies in prospective registries, and standardize ECMO management protocols to reduce complications.
OBJECTIVE: We aimed to evaluate the early and midterm mortality of young patients treated for cardiogenic shock with venoarterial extracorporeal membrane oxygenation (VA-ECMO) after adult cardiac surgery. METHODS: Studies reporting the outcome after postcardiotomy VA-ECMO in adult patients were identified through a systematic review of the literature. Individual patient-level data were provided by the authors of 10 studies. RESULTS: Data on 1268 patients treated at 25 hospitals were included in this study. Adjusted analysis identified 40 years of age as a cutoff value for in-hospital and mid-term mortality. Patients aged >40 years had significantly greater in-hospital mortality (1129 patients, crude rates 68.8% vs 43.1%, adjusted odds ratio, 3.267; 95% confidence interval, 1.970-5.425) and mortality at 24-month (109 patients, crude rates 73.7% vs 45.0%, adjusted hazard ratio, 3.530, 95% confidence interval, 2.571-4.844). Twelve (11.0%) patients aged ≤40 years received a ventricular assist device and heart transplantation, whereas this strategy was adopted in 33 (2.9%) patients aged >40 years ( CONCLUSIONS: The present findings suggest that early and midterm mortality after postcardiotomy VA-ECMO is significantly lower in patients aged ≤40 years compared to older patients. However, mortality remains substantial also among these young patients and heart-replacement therapies are infrequently performed in this subset of patients likely because of severe perioperative complications.